既往免疫治疗暴露患者放射性肺炎的剂量学预测因素:一项多中心分析
该多中心回顾性研究纳入五家机构192例既往接受ICI后行常规分割胸部IMRT的肺癌患者,中位随访14.7个月。多因素分析显示肿瘤位置和平均肺剂量(MLD)显著预测任何级别及≥2级肺炎,仅MLD显著预测≥3级肺炎。作者认为MLD是影响RP风险的最关键剂量-体积参数,数据或可为修订肺剂量约束提供依据。
要点
- 192例既往ICI后胸部IMRT肺癌患者中,1-5级RP发生率分别为21.9%、25.0%、8.3%、1.6%、1.0%。
- 多因素分析中肿瘤位置和MLD显著预测任何级别及≥2级肺炎,仅MLD显著预测≥3级肺炎。
- 作者认为MLD是免疫治疗时代影响RP风险的最关键剂量-体积参数。
核心结论
- 作者认为该研究是免疫治疗时代迄今最大规模的RP剂量学预测因素研究,显示MLD是影响RP风险的最关键剂量-体积参数。
- 作者认为这些数据或可为修订肺剂量约束以更好预防ICI/TRT人群RP提供依据。
研究设计与样本
- 回顾性汇集五家机构中既往接受ICI后行常规分割胸部调强放疗的肺癌患者。
- 共纳入192例患者,中位随访14.7个月。
- RP按CTCAE v5.0定义,统计采用逻辑回归建模和ROC分析。
主要发现
- 192例中多数为非小细胞肺癌、接受PD-1抑制剂、未与胸部放疗同期接受全身治疗。
- 1-5级RP发生率分别为21.9%、25.0%、8.3%、1.6%、1.0%。
- 1-5级RP患者平均MLD分别为10.7、11.6、12.6、14.7、12.8 Gy。
- 多因素分析中肿瘤位置和MLD显著预测任何级别及≥2级肺炎,仅MLD显著预测≥3级RP。
- ROC分析可对多种MLD阈值下的RP风险概率进行图示建模,或可作为胸部放疗计划制定时的辅助工具。
关键数值与推荐
- RP按CTCAE v5.0定义。
- 1-5级RP发生率分别为21.9%、25.0%、8.3%、1.6%、1.0%。
- 1-5级RP患者平均MLD分别为10.7、11.6、12.6、14.7、12.8 Gy。
- 多因素分析中肿瘤位置和MLD显著预测任何级别及≥2级肺炎,仅MLD显著预测≥3级RP。
临床怎么用
- 作者认为ROC分析对多种MLD阈值下RP风险概率的图示建模或可作为胸部放疗计划制定时的辅助工具。
- 作者认为这些数据或可为修订肺剂量约束以更好预防ICI/TRT人群RP提供依据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Combining immune checkpoint inhibitors (ICIs) and thoracic radiotherapy (TRT) may magnify the radiation pneumonitis (RP) risk. Dosimetric parameters can predict RP, but dosimetric data in context of immunotherapy are very scarce. To address this knowledge gap, we performed a large multicenter investigation to identify dosimetric predictors of RP in this under-studied population. MATERIALS AND METHODS: All lung cancer patients from five institutions who underwent conventionally-fractionated thoracic intensity-modulated radiotherapy with prior ICI receipt were retrospectively compiled. RP was defined per CTCAE v5.0. Statistics utilized logistic regression modeling and receiver operating characteristic (ROC) analysis. RESULTS: The vast majority of the 192 patients (median follow-up 14.7 months) had non-small cell lung cancer, received PD-1 inhibitors, and did not receive concurrent systemic therapy with TRT. Grades 1-5 RP occurred in 21.9%, 25.0%, 8.3%, 1.6%, and 1.0%, respectively. The mean MLD for patients with grades 1-5 RP was 10.7, 11.6, 12.6, 14.7, and 12.8 Gy, respectively. On multivariable analysis, tumor location and mean lung dose (MLD) significantly predicted for any-grade and grade ≥ 2 pneumonitis. Only MLD significantly predicted for grade ≥ 3 RP. ROC analysis was able to pictorially model RP risk probabilities for a variety of MLD thresholds, which can be an assistive tool during TRT treatment planning. CONCLUSION: This study, by far the largest to date of dosimetric predictors of RP in the immunotherapy era, illustrates that MLD is the most critical dose-volume parameter influencing RP risk. These data may provide a basis for revising lung dose constraints in efforts to better prevent RP in this rapidly expanding ICI/TRT population.
引用
- Bi J, Meng R, Yang D, et al. Dosimetric predictors of radiation pneumonitis in patients with prior immunotherapy exposure: A multi-institutional analysis. Radiother Oncol. 2023. PMID: 38042497. doi:10.1016/j.radonc.2023.110040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。